Cognition Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Cognition Therapeutics, Inc. (CGTX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $23.49 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-26
- Cognition Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $23.49M, a 30.86% decline from fiscal 2024.
- Cognition Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $33.97M.
- Cognition Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$25.77M.
- Cognition Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$21.38M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | $23.49M 10-K · filed 2026-03-26 | |
| 2024-12-31 | $33.97M 10-K · filed 2026-03-26 | -$33.97M 10-K · filed 2025-03-20 |
| 2023-12-31 | -$25.77M 10-K · filed 2025-03-20 | |
| 2022-12-31 | -$21.38M 10-K · filed 2024-03-26 | |
| 2021-12-31 | -$10.91M 10-K · filed 2023-03-23 | |
| 2020-12-31 | -$7.27M 10-K · filed 2022-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |